Press Release: Wednesday September 13, 12:00 pm Eastern Time
SOURCE: Immunex Corporation
Leslie Garrison, M.D., to Lead Immunex Clinical Development
SEATTLE, Sept. 13 /PRNewswire/ -- Immunex Corporation (Nasdaq: IMNX - news) announced today that Leslie Garrison, M.D., MPH, will lead the Immunex clinical development programs. Garrison, 42, will serve as senior vice president, clinical development, a promotion from her current vice president position at the company.
Dr. Garrison will take charge of the Immunex clinical development teams for all marketed products and product candidates, including ENBREL® (etanercept), NOVANTRONE® (mitoxantrone), LEUKINE® (sargramostim), and all Immunex product candidates, including NUVANCE(TM) (IL-4 receptor), AVREND(TM) (CD40 ligand), MOBISTA(TM) (flt3 ligand), TRAIL/Apo2L and other molecules in the Immunex pipeline. She will also lead the biometrics, pharmacokinetics and toxicology groups, with the respective vice presidents reporting directly to her.
``As an 11-year veteran of Immunex, Leslie has played a pivotal role in the clinical development of ENBREL and NUVANCE,'' said Peggy Phillips, chief operating officer and executive vice president. ``Her leadership skills and extensive knowledge of drug development are valuable assets in the critical link between discovery and commercialization.''
A graduate of SUNY at Stony Brook School of Medicine and Johns Hopkins University Graduate School of Hygiene and Public Health, Dr. Garrison was a research fellow at Johns Hopkins University prior to joining Immunex, and she also served as a clinical instructor in pediatrics at Johns Hopkins Hospital.
Dr. Garrison takes her position in succession to Ann Hayes, M.D., who continues her work at Immunex as senior medical director, focusing on Immunex's investigator IND program for ENBREL. After eight years of service as the senior vice president, medical development, and a number of years in the industry, Dr. Hayes will continue to play an important role in the future clinical development of ENBREL.
Immunex Corporation is a biopharmaceutical company dedicated to improving lives through immune system science innovations.
American Home Products Corporation owns a majority interest in Immunex. AHP is one of the world's largest research-based pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of prescription drugs, including biotechnological and vaccine products, animal health care products and over-the-counter medications.
NOTE: This news release contains forward-looking statements that involve risks and uncertainties, including risks associated with clinical development, regulatory approvals, our reliance on third-party manufacturers, product commercialization and other risks described from time to time in the SEC reports filed by Immunex, including the most recently filed Form 10-Q. An electronic version of this news release -- as well as additional information about Immunex of interest to investors, customers, future employees and patients -- is available on the Immunex home page at www.immunex.com.
SOURCE: Immunex Corporation |
